Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

The Ups and Downs of the START Trial with Stimuvax Immunotherapy
Author
Howard (Jack) West, MD

One of the highest profile clinical studies over the last few years has been the START trial of Stimuvax, also known as L-BLP-25 or tecemotide, an immunotherapy that looked promising in a randomized phase II trial that led to a subsequent phase III trial that administered Stimuvax or placebo after chemo and radiation for locally advanced (stage III) NSCLC, as described more in this post about STIMUVAX and the START trial from early 2007.

Over the next five years, the level of anticipation over the trial was remarkable.  Though oncologists specializing in lung cancer were hopeful about it, financial analysts and patient/caregiver communities became exceptionally focused on the trial, many people becoming essentially convinced it was a "can't miss" trial long before the trial was completed.

Unfortunately, we received news at the beginning of this year that the START trial failed to meet its primary endpoint of significantly improving overall survival with Stimuvax.  Without any specific information of results beyond this, I did a video post to address the implications of the negative START trial, primarily noting that a negative trial for Stimuvax doesn't mean that other immunotherapies aren't promising and won't work. 

At ASCO 2013, we actually saw the data from the trial, which led me to question whether these results should be boiled down to just being considered "positive" or "negative", effective or useless.  Specifically, the trial showed a modest, 3.3 month longer median overall survival in the 829 recipients of Stimuvax compared to the 410 recipients of placebo (the randomization was 2:1 for the active treatment), but there was a whopping 10.2 month difference in favor of Stimuvax recipients when the analysis was limited to the 65% of patients on the trial who had previously received their chemo and radiation concurrently, as opposed to sequentially.

Survival in Entire Population, START Trial Survival in Entire Population, START Trial

 

Survival in Concurrent CTRT Pts, START Trial Survival in Concurrent CTRT Pts, START Trial

When these data were presented at the ASCO meeting, I noted that a 10.2 month difference in overall survival is rather remarkable, even if it was a subset analysis (806 patients) of a larger trial. That's quite far from a complete strikeout. In fact, I found it very encouraging. However, when you look at the survival curves in the lower figure, you can appreciate that the curves just happen to separate hugely in the middle, then converge by 4 years out.

Unfortunately, this means that Stimuvax isn't curing patients, which is what we really hoped might happen. Instead, a subset of patients may be doing better for a few months, but it's not converting more potentially curable patients from "not cured" to "cured".

Word on the street is that Merck KGA, the company developing Stimuvax, or tecemotide, is planning a START trial redux that only enrolls patients who received concurrent chemo/radiation. We don't know why the results seem to be different and more favorable in these patients, but this is the preferred and more curative treatment approach, so there may be some significant difference by which the locally advanced NSCLC patients who are good candidates for concurrent chemo/radiation truly benefit from this immunotherapy. However, even if a subsequent trial shows a survival difference, it will be important to clarify whether this therapy is actually curing patients who wouldn't otherwise be cured or "merely" prolonging survival for several months. The latter is still a helpful development, but it's not as valuable as curing more patients with lung cancer.

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on